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Nitric oxide (NO) is a gaseous messenger molecule syn-
thesized from L-arginine and molecular oxygen by three
different NO synthases, that is, neuronal (nNOS), endothelial
(eNOS), and inducible (iNOS) form [1]. Since its discovery
in the early 1980s by the three Nobel Laureates Furchgott,
Ignarro & Murad [2], NO has been widely recognised as
an important signalling molecule in many physiological
processes.The initial identification of NO as an endothelium-
derived relaxing factor (EDRF) [3] generated great interest
in its function in vascular biology. Over the following years,
however, the focus on NO research rapidly expanded from
the vascular system to its role in immunity and inflammation,
the nervous system, pregnancy, aging, and cell death.
Many studies suggest that excessive or abnormal produc-
tion of NO plays a crucial role in neuronal cell death asso-
ciated with neurodegenerative disorders such as Alzheimer’s
and Parkinson’s diseases, as well as various conditions of
vascular dysfunction. At physiological levels, NO is essential
for neuronal function, differentiation and survival through
activation of signalling pathways that include the cyclic
guanosine monophosphate (cGMP)/soluble guanylyl cyclase
pathway [4] and S-nitrosylation, in which NO reversibly
binds to thiol groups of proteins [5]. The vast network of
NO-associated signalling paradigms further includes acety-
lation/deacetylation and methylation/demethylation modifi-
cations and peroxynitrite formation (leading to nitrotyrosi-
nation of protein residues), as well as modulation of gene
expression via epigenetic changes [5–8]. How controlled S-
nitrosylation/nitrotyrosination of proteins and activation of
the NO/cGMP signalling pathway promote cellular survival
and induce epigenetic changes while uncontrolled signalling
promotes cell death and dysfunction remains to be eluci-
dated. The aim of this Special Issue is to gather information
encapsulating the above signalling pathways.
The articles published in this Special Issue largely cover
(1) NO signalling in neuronal function and disease as well as
(2) vascular targets in endothelial function and dysfunction,
both of which involve the broad range of actions of this
signalling molecule. In order to understand the contribution
of NO to neuronal dysfunction, one has to consider that NO
is a crucial molecule in cellular physiology. Numerous studies
show the involvement of NO in neuronal development,
plasticity, excitability, and transmission [8–12]. However, the
common mechanisms across several neurodegenerative dis-
orders relate to the neurotoxicity of NO and its downstream
reactive nitrogen species (RNS). Enhanced nitrotyrosine
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immunoreactivity is evident in brains from patients with
Alzheimer’s and Parkinson’s disease. Nitrated proteins are
associated with 𝛽-amyloid deposition and nitrotyrosination
of Tau protein and synaptophysin has been reported in brain
samples from patients with Alzheimer’s disease.The potential
downstream signalling pathways of these posttranslational
modifications are discussed in the review by S. A. Bradley
and J. R. Steinert in this Issue. The cellular roles of NO in
neurodegenerative disease, such as Alzheimer’s, are reviewed
by R. Balez and L. Ooi with a focus on neurotoxicity versus
neuroprotection while the role of aberrant NO signalling in
neurodevelopmental disorders such as Fragile X syndrome is
investigated in the study by E. Lima-Cabello et al.
Other topics of this issue focus on aspects of vascular NO
signalling with particular interest in fetoplacental dysfunc-
tion caused by abnormal eNOS regulation (as discussed by
A. Leiva et al.). Endothelial function and eNOS regulation
are essential for healthy cardiovascular responses but are also
critical for adaptations during pregnancy. Several diseases
associated with vascular dysfunction such as atherosclero-
sis, diabetes mellitus, hypertension, or preeclampsia involve
altered NO signalling [13–15].
The paper by A. Leiva et al. reviews the mechanisms
leading to abnormal NO signalling, which include reduced
bioavailability of L-arginine (NOS substrate) and tetrahydro-
biopterin (BH
4
), abnormal calcium-calmodulin signalling,
and activation and inhibition of eNOS activity through
phosphorylation of Ser1177 or Thr495, respectively [16]. NO
has also been reported to play a crucial role in the transition
of fetoplacental endothelial cells from a mitogenic to a
metabolic phenotype in themacrocirculation, comparedwith
a change from a metabolic to a mitogenic phenotype in
the microcirculation in response to insulin in gestational
diabetes mellitus [17]. Thus, the actions of NO are not
only important during vascular adaptations to pregnancy
and related dysfunctions but also essential during vascular
signalling induced by physical training resulting in elevated
nitrite and nitrate levels as reported in the study by A. M.
Jacomini et al.
Together, this Special Issue highlights the tremendous
diversity of NO signalling pathways with regard to its
function in health and disease. All contributing publications
have emphasised that NO represents an important signalling
molecule and future research required in this field will extend
the understanding of the broad actions of NO.
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